Glioblastoma multiforme (GBM) is a fast-growing type of gliomas, which are the most common form of primary tumors of the central nervous system (CNS). According to the WHO, “Glioblastoma multiforme is the most common and lethal primary malignancy for which the median survival time for patients is only 14.6 months”.
As of today there is no cure for Glioblastoma. However, in the coming years, the outlook for patients with glioblastoma multiforme is anticipated to improve.
Some of the key companies such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharm, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals are running several clinical trials investigating different pipeline therapies at the various clinical stage of development in Glioblastoma multiforme market.
Source: FAQs About Glioblastoma Multiforme